4SC AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
December 19, 2019 at 05:35 am EST
Share
DGAP Voting Rights Announcement: 4SC AG
4SC AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
19.12.2019 / 11:30
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
4SC AG
Street:
Fraunhoferstr. 22
Postal code:
82152
City:
Planegg-Martinsried Germany
Legal Entity Identifier (LEI):
391200QOKN7LGVP0RQ86
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Legal entity: ATHOS KG City of registered office, country: München, Germany
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
5. Date on which threshold was crossed or reached:
16 Dec 2019
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
69.98 %
0 %
69.98 %
45972769
Previous notification
n/a %
n/a %
n/a %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE000A14KL72
32171664
%
69.98 %
Total
32171664
69.98 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
%
Total
%
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
%
Total
%
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
ATHOS KG
0 %
%
0 %
Santo Holding AG, Zug
0 %
%
0 %
Santo Holding (Deutschland) GmbH
45.85 %
%
45.85 %
ATHOS KG
0 %
%
0 %
ATS Beteiligungsverwaltung GmbH
24.13 %
%
24.13 %
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
As of 16 December 2019, ATHOS KG is the parent company of Santo Holding (Deutschland) GmbH and ATS Beteiligungsverwaltung GmbH.
Date
16 Dec 2019
19.12.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Companyâs product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.